IN2014DN07283A - - Google Patents

Info

Publication number
IN2014DN07283A
IN2014DN07283A IN7283DEN2014A IN2014DN07283A IN 2014DN07283 A IN2014DN07283 A IN 2014DN07283A IN 7283DEN2014 A IN7283DEN2014 A IN 7283DEN2014A IN 2014DN07283 A IN2014DN07283 A IN 2014DN07283A
Authority
IN
India
Prior art keywords
group
alkyl group
substituent
cancer agent
hydrogen atom
Prior art date
Application number
Other languages
English (en)
Inventor
Tetsuya Sugimoto
Hidekazu Takahashi
Morihiro Mitsuya
Norio Masuko
Hiroshi Sootome
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of IN2014DN07283A publication Critical patent/IN2014DN07283A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
IN7283DEN2014 2012-02-29 2013-02-27 IN2014DN07283A (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012043303 2012-02-29
JP2012186534 2012-08-27
PCT/JP2013/055064 WO2013129443A1 (ja) 2012-02-29 2013-02-27 新規ピペリジン化合物又はその塩

Publications (1)

Publication Number Publication Date
IN2014DN07283A true IN2014DN07283A (da) 2015-04-24

Family

ID=49082638

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7283DEN2014 IN2014DN07283A (da) 2012-02-29 2013-02-27

Country Status (21)

Country Link
US (3) US9346787B2 (da)
EP (1) EP2821406B1 (da)
JP (1) JP5323289B1 (da)
KR (1) KR101677823B1 (da)
CN (1) CN104159893B (da)
AU (1) AU2013227024B2 (da)
BR (1) BR112014021519B1 (da)
CA (1) CA2865875C (da)
DK (1) DK2821406T3 (da)
ES (1) ES2576497T3 (da)
HK (1) HK1199730A1 (da)
HU (1) HUE028495T2 (da)
IN (1) IN2014DN07283A (da)
MX (1) MX344276B (da)
MY (1) MY169179A (da)
PL (1) PL2821406T3 (da)
PT (1) PT2821406T (da)
RU (1) RU2581834C1 (da)
SG (1) SG11201405318PA (da)
TW (1) TWI485146B (da)
WO (1) WO2013129443A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
US9012475B2 (en) 2013-08-27 2015-04-21 Taiho Pharmaceutical Co., Ltd. Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor
KR101430209B1 (ko) * 2014-03-06 2014-08-14 강원대학교산학협력단 단백질 키나아제 활성 측정 방법 및 이를 위한 키트
TWI693218B (zh) * 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光a激酶抑制劑
CN104758286B (zh) * 2015-03-05 2016-09-14 南京工业大学 1-苄基-4-(2,4-二氯苯乙胺基)哌啶在制备抗肿瘤药物中的应用
CN110088097A (zh) * 2016-12-22 2019-08-02 大鹏药品工业株式会社 取代的哌啶化合物的盐
MA52793A (fr) 2018-05-29 2021-04-14 Taiho Pharmaceutical Co Ltd Agent antitumoral et méthode de traitement d'une tumeur
CN112239465A (zh) * 2019-07-16 2021-01-19 微境生物医药科技(上海)有限公司 极光激酶抑制剂及其用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
WO2023005957A1 (en) * 2021-07-28 2023-02-02 Jacobio Pharmaceuticals Co., Ltd. Polymorphic forms of aurora a selective inhibitors and uses thereof
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105090A1 (en) 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
WO2006046734A2 (ja) * 2004-10-29 2006-05-04 Banyu Pharma Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
ATE542814T1 (de) * 2005-08-18 2012-02-15 Vertex Pharma Pyrazinkinaseinhibitoren
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
ES2535854T3 (es) 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
MX2008011769A (es) * 2006-03-20 2008-09-25 Hoffmann La Roche Derivados de ftalazinona pirazol, su fabricacion y uso como agentes farmaceuticos.
WO2007107469A1 (en) 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Methods of inhibiting btk and syk protein kinases
JP2008081492A (ja) * 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
GB0705656D0 (en) 2007-03-23 2007-05-02 Addex Pharmaceuticals Sa Novel compounds E1
WO2008156721A1 (en) 2007-06-20 2008-12-24 Merck & Co., Inc. Diphenyl substituted alkanes
US8519136B2 (en) 2008-02-22 2013-08-27 Msd K.K. Aminopyridine derivatives having aurora a selective inhibitory action
JP2012521425A (ja) * 2009-03-23 2012-09-13 Msd株式会社 オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
AU2010229140A1 (en) * 2009-03-24 2011-11-10 Msd K.K. Novel aminopyridine derivatives having Aurora A selective inhibitory action
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof

Also Published As

Publication number Publication date
EP2821406A4 (en) 2015-04-29
US20160228427A1 (en) 2016-08-11
SG11201405318PA (en) 2014-11-27
CA2865875A1 (en) 2013-09-06
EP2821406A1 (en) 2015-01-07
HUE028495T2 (hu) 2016-12-28
WO2013129443A1 (ja) 2013-09-06
JP5323289B1 (ja) 2013-10-23
ES2576497T3 (es) 2016-07-07
US20150045342A1 (en) 2015-02-12
JPWO2013129443A1 (ja) 2015-07-30
KR20140129056A (ko) 2014-11-06
MX344276B (es) 2016-12-08
CA2865875C (en) 2016-06-21
AU2013227024A1 (en) 2014-09-18
TWI485146B (zh) 2015-05-21
HK1199730A1 (zh) 2015-07-17
BR112014021519A2 (da) 2017-06-20
CN104159893B (zh) 2016-05-11
TW201339150A (zh) 2013-10-01
MX2014010395A (es) 2015-06-05
US20180369224A1 (en) 2018-12-27
PL2821406T3 (pl) 2016-11-30
KR101677823B1 (ko) 2016-11-18
PT2821406T (pt) 2016-09-07
EP2821406B1 (en) 2016-06-01
US9346787B2 (en) 2016-05-24
AU2013227024B2 (en) 2015-12-10
DK2821406T3 (da) 2016-08-22
CN104159893A (zh) 2014-11-19
US10092556B2 (en) 2018-10-09
RU2581834C1 (ru) 2016-04-20
MY169179A (en) 2019-02-25
BR112014021519B1 (pt) 2022-05-24

Similar Documents

Publication Publication Date Title
IN2014DN07283A (da)
PH12018502633A1 (en) Substituted pyridines as inhibitors of dnmt1
PH12014501719A1 (en) Pyridone derivatives
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
NZ715747A (en) Syk inhibitors
MD4666B1 (ro) Inhibitori ai Syk
MX2014011829A (es) Compuestos de piridinilideno n-sustituidos y derivados para combatir plagas de animales.
EA201690752A1 (ru) Ингибиторы g12c kras
MX2013004407A (es) Derivado de piridina y agente medicinal.
TR201905814T4 (tr) Jak inhibitörü olarak bipirazol tuzu.
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
TN2012000608A1 (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
MA34064B1 (fr) Compose heterocyclique
EP2613782A4 (en) INDAZOLE DERIVATIVES AS INHIBITORS OF THE ERK PATHWAY
TN2012000609A1 (en) Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
MX2013011551A (es) Compuestos y derivados hetero - biciclicos n - sustituidos para combatir las pestes en animales.
EA201391629A1 (ru) Ингибиторы цсж-1r для лечения опухолей головного мозга
RS52964B (en) 7-PIPERIDINOALKIL-3,4-DIHYDROKVINOLONE DERIVATIVE
IN2014DN07509A (da)
JO3509B1 (ar) معدلات p2x7
EA201391558A1 (ru) Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
EP2585446A4 (en) COMPOUNDS WITH ANTAGONISTIC EFFECT AGAINST TRPV1 AND THEIR USE
MX2015007116A (es) Nuevos derivados de 1,4-ditiina sustituida y su uso como fungicidas.